Small measuring inconsistencies between sessions are normal
Timing Optional Monitoring guidance is pathway-based because compound-specific clinical monitoring standards for AOD-9604 are not established
What's happening internally: AOD 9604 is binding to receptors, initiating lipolysis, and shifting your metabolism toward fat oxidation
Across all six studies, the safety findings were consistent: no serious adverse events, no immunogenic responses, no changes in IGF-1, no glucose or insulin disruption
Pinch a fold of skin at the injection site
Hey I haven't started the new meds because I work in London so I keep running out of time to get my prescription picked up, but I will have to adopt a new skin regime recommended to me by the dermatologist for 2 months